Bio Data Bridges Awarded Funding for Recombinant Proteomic Data Resource

SEATTLE, WA, UNITED STATES - Jan 5, 2017 - Transform Research, LLC dba Bio Data Bridges, a life science software and knowledge management company, received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences (NIGMS). The grant will fund collaborative research between Bio Data Bridges and several research institutes in the Seattle metropolitan area and throughout the US.  The long-term goal is to develop the Recombinant Proteomic Data Resource (RPDR) for protein researchers to better share unpublished positive and negative research outcomes.

 “We are excited about this Phase I SBIR award from NIGMS, as it validates the significance of the technology we are developing,” stated Peter Nollert, Bio Data Bridges co-founder, and Business Director. “The unique properties of our technology provide the basis for productivity increases and better reproducibility of recombinant protein production. Our approach allows researchers to easily share data that is currently unpublishable via traditional publication routes, but is key to fellow-researchers when they want to create recombinant protein samples. In addition, the underlying technology has potentially broad applications in commercial markets outside of biotechnology.”

Mark Mixon, Bio Data Bridges co-founder and Technical Director, agreed with Peter Nollert’s sentiment. “Our Recombinant Proteomic Data Resource will impact many protein researchers and help scientists research and design experiments with less effort. We are excited to add new collaborators to our emerging platform.”

This research is built on top of years of hands-on experience in recombinant protein production in the biotechnology marketplace. The Recombinant Proteomic Data Resource will be developed and its utility validated by systematically collecting recombinant protein production trials information, regardless of their outcome, in a way that does not require cumbersome reformatting of native data formats. Users of the system gain currently inaccessible key insight for new protein production. The Phase1 SBIR validation study aims at releasing a minimum of 20,000 records that are currently inaccessible to researchers, and present these in a format that supports new experiment design. Protein researchers that are seeking new ways to share their ‘invisible‘ protein production results with the wider scientific community and get credit for such, are welcome to join during the development of the system and are encouraged to enquire via proteindata.cloud.

- Ends -

Transform Research, LLC dba Bio Data Bridges is a life science software and knowledge management company that is on a path to develop and commercialize products aimed at leveraging existing information to simplify protein sample production by means of aggregating, mining and disseminating gene-to-protein knowledge.

For more information, please visitwww.biodatabridges.comandproteindata.cloud  

Contact: Peter Nollert | 206.495.2342 | pnollert@biodatabridges.com

RPDR™ is a trademark of Bio Data Bridges

The Recombinant Proteomic Data Resource is funded by NIGMS grant 1R43GM121116-01